Victory Capital Management Inc. Has $47.58 Million Position in Charles River Laboratories Intl. Inc (NYSE:CRL)

Victory Capital Management Inc. boosted its stake in Charles River Laboratories Intl. Inc (NYSE:CRL) by 1.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 434,706 shares of the medical research company’s stock after buying an additional 6,153 shares during the period. Victory Capital Management Inc. owned 0.92% of Charles River Laboratories Intl. worth $47,578,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. California Public Employees Retirement System boosted its position in shares of Charles River Laboratories Intl. by 2.1% in the 2nd quarter. California Public Employees Retirement System now owns 68,100 shares of the medical research company’s stock valued at $6,888,000 after purchasing an additional 1,400 shares during the period. Parametric Portfolio Associates LLC boosted its position in shares of Charles River Laboratories Intl. by 4.2% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 103,108 shares of the medical research company’s stock valued at $10,429,000 after purchasing an additional 4,150 shares during the period. Stifel Financial Corp acquired a new position in shares of Charles River Laboratories Intl. in the 2nd quarter valued at $261,000. AHL Partners LLP boosted its position in shares of Charles River Laboratories Intl. by 209.7% in the 2nd quarter. AHL Partners LLP now owns 21,810 shares of the medical research company’s stock valued at $2,206,000 after purchasing an additional 14,767 shares during the period. Finally, Shelton Capital Management acquired a new position in shares of Charles River Laboratories Intl. in the 2nd quarter valued at $348,000. 97.13% of the stock is currently owned by institutional investors.

Charles River Laboratories Intl. Inc (NYSE CRL) traded down $0.29 during mid-day trading on Thursday, hitting $110.02. The stock had a trading volume of 16,543 shares, compared to its average volume of 454,566. The company has a market capitalization of $5,106.20, a P/E ratio of 43.43, a P/E/G ratio of 1.60 and a beta of 0.74. Charles River Laboratories Intl. Inc has a 12 month low of $86.25 and a 12 month high of $119.05. The company has a current ratio of 1.78, a quick ratio of 1.62 and a debt-to-equity ratio of 1.06.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Tuesday, February 13th. The medical research company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.14. Charles River Laboratories Intl. had a return on equity of 26.14% and a net margin of 6.64%. The business had revenue of $478.50 million during the quarter, compared to the consensus estimate of $475.02 million. During the same quarter in the prior year, the company posted $1.21 earnings per share. The firm’s revenue was up 2.5% on a year-over-year basis. analysts predict that Charles River Laboratories Intl. Inc will post 5.52 EPS for the current year.

A number of brokerages have commented on CRL. SunTrust Banks upgraded Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and raised their price objective for the stock from $107.66 to $125.00 in a research report on Wednesday. Credit Suisse Group reaffirmed a “hold” rating and set a $108.00 price target on shares of Charles River Laboratories Intl. in a research note on Thursday. Royal Bank of Canada set a $116.00 price objective on Charles River Laboratories Intl. and gave the company a “hold” rating in a research note on Tuesday. TheStreet lowered Charles River Laboratories Intl. from an “a-” rating to a “c+” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. lifted their price objective on Charles River Laboratories Intl. from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $114.85.

In other news, Director Online Communications Bdirect sold 131,000 shares of the company’s stock in a transaction dated Thursday, January 18th. The stock was sold at an average price of $0.29, for a total transaction of $37,990.00. Also, Director Robert J. Bertolini sold 3,609 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $110.22, for a total value of $397,783.98. The disclosure for this sale can be found here. Over the last three months, insiders sold 195,673 shares of company stock valued at $2,644,046. Insiders own 2.20% of the company’s stock.

WARNING: This report was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://weekherald.com/2018/02/15/victory-capital-management-inc-has-47-58-million-stake-in-charles-river-laboratories-intl-inc-crl.html.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply